Announcements Trials
Browse Landscape

Status

No longer available 1Approved for marketing 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 3151Observational 40Expanded_access 2

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Mesothelioma 1

Interventions

3-Iodobenzylguanidine 9Amifampridine 6nilotinib 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5trametinib 4pembrolizumab 4gallium 68 PSMA-11 4fludarabine 4elotuzumab 4dabrafenib 4Nivolumab 4Bortezomib 4Afatinib 4venetoclax 3regorafenib 3midostaurin 3fludarabine phosphate 3TIC10 compound 3Sunitinib 3Prednisone 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Crizotinib 3Capecitabine 3Axitinib 3Alpelisib 3Abiraterone Acetate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × Cisplatin × Clear all
NCT02985658 2021-07-21

Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

University of Washington

No longer available
Breast

Triple Negative Breast Neoplasms

NCT00040625 2007-03-15

ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.

Eli Lilly and Company

Approved for marketing
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡